Literature DB >> 20457591

Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics.

Diana M Brainard1, Evan J Friedman, Bo Jin, Sheila A Breidinger, Maria D Tillan, Larissa A Wenning, Julie A Stone, Jeffrey A Chodakewitz, John A Wagner, Marian Iwamoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20457591     DOI： 10.1177/0091270010367652

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  15 in total

1.  Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir.

Authors:  Ivy Song; Julie Borland; Shuguang Chen; Parul Patel; Toshihiro Wajima; Amanda Peppercorn; Stephen C Piscitelli
Journal:  Antimicrob Agents Chemother       Date:  2011-12-19       Impact factor: 5.191

2.  Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients.

Authors:  Matthew L Rizk; Yaming Hang; Wen-Lin Luo; Jing Su; Jing Zhao; Havilland Campbell; Bach-Yen T Nguyen; Peter Sklar; Joseph J Eron; Larissa Wenning
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

3.  Pharmacokinetic determinants of virological response to raltegravir in the in vitro pharmacodynamic hollow-fiber infection model system.

Authors:  Ashley N Brown; Jonathan R Adams; Dodge L Baluya; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

4.  Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.

Authors:  Krishan K Pandey
Journal:  Clin Med Rev Ther       Date:  2011-12-20

5.  Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age.

Authors:  Matthew L Rizk; Lihong Du; Chantelle Bennetto-Hood; Larissa Wenning; Hedy Teppler; Brenda Homony; Bobbie Graham; Carrie Fry; Sharon Nachman; Andrew Wiznia; Carol Worrell; Betsy Smith; Edward P Acosta
Journal:  J Clin Pharmacol       Date:  2015-04-13       Impact factor: 3.126

6.  Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection.

Authors:  Uriel Sandkovsky; Susan Swindells; Ryan Moore; Edward P Acosta; Courtney V Fletcher
Journal:  Pharmacotherapy       Date:  2012-02       Impact factor: 4.705

7.  Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling.

Authors:  Xiaomei I Liu; Jeremiah D Momper; Natella Y Rakhmanina; Dionna J Green; Gilbert J Burckart; Tim R Cressey; Mark Mirochnick; Brookie M Best; John N van den Anker; André Dallmann
Journal:  Clin Pharmacokinet       Date:  2020-11       Impact factor: 6.447

8.  Divalent metals and pH alter raltegravir disposition in vitro.

Authors:  Darren M Moss; Marco Siccardi; Matthew Murphy; Michael M Piperakis; Saye H Khoo; David J Back; Andrew Owen
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

Review 9.  Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review.

Authors:  Anthony T Podany; Kimberly K Scarsi; Michelle M Pham; Courtney V Fletcher
Journal:  Clin Pharmacokinet       Date:  2020-09       Impact factor: 6.447

10.  Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers.

Authors:  Marc Weiner; Eric F Egelund; Melissa Engle; Melissa Kiser; Thomas J Prihoda; Jonathan A L Gelfond; William Mac Kenzie; Charles A Peloquin
Journal:  J Antimicrob Chemother       Date:  2013-12-15       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.